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Abstract
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in
a Phase I study with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs) loaded
with a mixture of apoptotic/necrotic allogeneic melanoma cell lines (Apo-Nec), to evaluate toxicity
and immune responses. Also, IL-10 1082 genotype was analyzed in an effort to predict disease
progression.
Methods: PBMC were obtained after leukapheresis and DCs were generated from monocytes
cultured in the presence of GM-CSF and IL-4 in serum-free medium. Immature DCs were loaded
with gamma-irradiated Apo-Nec cells and injected id without adjuvant. Cohorts of four patients
were given four vaccines each with 5, 10, 15, or 20 × 106 DC/Apo-Nec cell per vaccine, two weeks
apart. Immune responses were measured by ELISpot and tetramer analysis. Il-10 genotype was
measured by PCR and corroborated by IL-10 production by stimulated PBMC.
Results: Immature DCs efficiently phagocytosed melanoma Apo-Nec cells and matured after
phagocytosis as evidenced by increased expression of CD83, CD80, CD86, HLA class I and II, and
75.2 ± 16% reduction in Dextran-FITC endocytosis. CCR7 was also up-regulated upon Apo-Nec
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uptake in DCs from all patients, and accordingly DC/Apo-Nec cells were able to migrate in vitro
toward MIP-3 beta. The vaccine was well tolerated in all patients. The DTH score increased
significantly in all patients after the first vaccination (Mann-Whitney Test, p < 0.05). The presence
of CD8+T lymphocytes specific to gp100 and Melan A/MART-1 Ags was determined by ELISpot and
tetramer analysis in five HLA-A*0201 patients before and after vaccination; one patient had stable
elevated levels before and after vaccination; two increased their CD8 + levels, one had stable
moderate and one had negligible levels. The analysis of IL-10 promoter -1082 polymorphism in the
sixteen patients showed a positive correlation between AA genotype, accompanied by lower in vitro
IL-10 production by stimulated PBMC, and faster melanoma progression after lymph nodes surgery
(p = 0.04). With a mean follow-up of 49.5 months post-surgery, one stage IIC patient and 7/8 stage
III patients remain NED but 7/7 stage IV patients have progressed.
Conclusion: We conclude that DC/Apo-Nec vaccine is safe, well tolerated and it may induce
specific immunity against melanoma Ags. Patients with a low-producing IL-10 polymorphism appear
to have a worst prognosis.
Trial registration: Clinicaltrials.gov (NHI) NCT00515983
Background
Melanoma incidence is constantly rising, but little
progress has been made in its treatment. Clinical outcome
is highly variable, and prognosis is poor when distant
metastases are present [1]. Among the current therapeutic
strategies, high dose IFN alpha in stage III patients
increases disease-free survival but not overall survival [2],
and chemotherapy is seldom useful to control disease
progression. Since there is increasing evidence indicating
a central role for T lymphocytes in effective immune
responses against cancer, considerable efforts are being
focused in the field of cancer immunotherapy [3,4]. Den-
dritic cells (DCs) are professional antigen-presenting cells
(APC) that can initiate and regulate T-cell responses by
their extraordinary capacity to stimulate naïve T lym-
phocytes [5,6]. A large variety of antigens (Ags) have been
described in melanoma, such as Melan A/MART-1 [7],
gp100 [8], MAGE-3 [9], Tyrosinase [10], TRP-2 [11], GD2,
GD3 [12] and NY-ESO-1 [13]. Diverse strategies have
been reported to generate and assay tumor-specific DC
vaccines, which vary in the method of loading Ags in the
DCs, in the administration route of the vaccines and in
the clinical stage of the patients treated. A randomized
trial of autologous peptide-pulsed DCs as vaccines versus
DTIC in stage IV melanoma patients did not reveal any
advantage between groups [14]. The use of whole tumor
cells as a source of Ags has the theoretical potential to
elicit a broader immune response to tumor-associated Ags
than it would be achieved by pulsing DCs with defined
tumor Ags. Thus, Salcedo et al [15] have performed a
Phase I/II study on melanoma patients using as vaccines
blood monocyte-derived immature DCs (iDCs) loaded
with a lysate of a melanoma cell line; they obtained a
complete response in 1/15 patients and strong immune
specific response against melanoma Ags in 1/5 HLA*0201
patients. Another recent clinical study on 20 melanoma
patients demonstrated that ex vivo generated DCs loaded
with a killed melanoma cell line also induced two clinical
responses, one complete and one partial [16]. The low
rates of clinical responses obtained, although they consti-
tute a proof of principle, clearly suggest that this type of
vaccines should be ameliorated and that other factors,
such as the tumor burden and the intrinsic capacity of the
patient to react to immunization, should be also consid-
ered to evaluate responses. Previous results from our lab-
oratory demonstrated that immunizing mice with iDCs
loaded with melanoma B16 apoptotic/necrotic cells effi-
ciently primed both CD4+ and CD8+ T cells and protected
80% of mice against intracutaneous challenge with live
B16 cells. This immunization procedure also induced a
tumor-specific memory response protecting the animals
against a second challenge 10 weeks after vaccination
[17]. We and others [18-21] have shown that DC phago-
cytosis of apoptotic and necrotic tumor cells allows cross-
presentation of tumor Ags. Here we describe a human DC-
vaccine named DC/Apo-Nec composed of autologous ex
vivo generated DCs that have phagocytosed an apoptotic/
necrotic mixture of four allogeneic melanoma cell lines
[21] expressing known melanoma-associated Ags. DC/
Apo-Nec cells efficiently cross – presented gp100 and
Melan A/MART-1 Ags to induce IFN-γ secretion by specific
CTL clones [21]. As previously discussed, melanoma
patients respond quite differently to the same vaccination
protocol. Since cytokines play a crucial role in the host's
immune response, and in view of recent reports that asso-
ciate melanoma patients outcome with some cytokine
gene polymorphisms [22-24], we investigated preliminar-
ily if IL-10 -1082 promoter genotype, which influences
cytokine levels in vitro [25], could be related to the overall
evolution of the patients participating in the study.
Although IL-10 is mainly regarded as an immunosuppres-
sive cytokine, preclinical models as well as observations inJournal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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humans suggest that it might have a facilitator role in pre-
conditioning tumors to immune recognition [26]. Also, a
growing number of reports have suggested an antiang-
iogenic role for IL-10 [27,28].
In this study, we present the results of a Phase I Clinical
Trial of DC/Apo-Nec vaccine in 16 melanoma patients
stages IIC, III and IV. We have evaluated the toxicity of
DC/Apo-Nec vaccine, the phenotypic characteristics of
DCs from treated patients and investigated the T cell
responses to Melan A/MART-1 and gp100 Ags in HLA-
A*0201 patients by ELISpot and tetramer analysis. The
presence of the IL-10 promoter -1082 AA polymorphism
in this group of patients appears related to a worst evolu-
tion of the disease.
Methods
Study design and eligibility criteria
This study was designed as a Phase I clinical trial to evalu-
ate toxicity, feasibility and immune responses to vaccina-
tion, and received approval from the Institutional Review
Board of the Instituto Alexander Fleming, from an inde-
pendent Ethics Committee and from the ANMAT, Minis-
try of Health (Argentina). Eligibility criteria for patients
were: (a) histologically confirmed cutaneous melanoma
stages IIB, IIC, III or IV (AJCC); (b) patients with minimal
or non-detectable disease (NED) after surgery as asserted
by CAT scans. Melanoma patients with unknown primary
tumor site could be included in the study; (c) ages
between 15 and 60 years; (d) life expectancy > 6 months;
(e) performance status (ECOG) 0 or 1; (f) patients with
stage III disease had to be previously treated with IFN-
alpha, and either finished the treatment or suspended it
due to disease progression, toxicity or other clinical rea-
sons. Alternatively, patients who had not started IFN-
alpha within six months after surgery could be included in
this study; (g) a suitable venous access for the leukapher-
esis procedure; (h) laboratory eligibility criteria included:
hemoglobin > 10 gr %; WBC count > 4800/mm3, platelets
> 150.000/mm3, total and direct billirubin, serum oxa-
lacetic transaminase and glutamic pyruvic transaminase <
1.5 fold the upper normal value; LDH ≤ 450 mU/ml; i)
absence of pregnancy, with serum βHCG determined one
week before vaccination in pre-menopausal women; (i)
serum creatinine < 1.4 mg %; (k) no chemotherapy, radi-
otherapy or any biological treatments during the previous
month; (k) no concurrent medication with corticosteroids
or NSAIDs; (l) no active brain metastases; (m) normal
ECG; (n) all patients gave written informed consent
before inclusion in the Study.
Evaluation of patients and treatment schedule
The baseline tumor evaluation was performed within 35
days prior to the first vaccination. Clinical evaluation
included a complete medical history; physical examina-
tion; ECG; complete CAT scans (brain, thorax, abdomen
and pelvis) to determine tumor staging, tumor burden
and sites of disease; blood chemistry and hematology.
Physical examination was also performed at the time of
each vaccination. Eligible patients underwent on day -30
a leukapheresis procedure to obtain PBMC (peripheral
blood mononuclear cells) to generate DCs. Patients
received four vaccinations at 2-week intervals, starting at
day 0. Vaccination consisted in the intradermal injection
of the corresponding vaccine dose (5–20 × 106 DC/Apo-
Nec cells in 300 μl sterile medium) and a DTH reaction in
the forearm with 2 × 106irradiated apoptotic-necrotic
tumor cells in 100 μl sterile medium without adjuvant.
Patients' vital signs and skin reactions were monitored 2
hs after vaccination and DTH was also evaluated 24 and
48 hs post-vaccination. At day 56, the patients underwent
laboratory analysis and 40 ml blood extraction to isolate
PBMC and serum. At day 70th, the patients' status were
investigated with abdominal echography and chest X-rays
and at day 75th the study ended with a clinical examina-
tion.
Evaluation criteria and statistical analysis
The evaluable population was composed of patients who
received the four vaccinations. Because most data groups
were not normally distributed, all data were analyzed by
the Wilcoxon's rank sum test. All adverse events were clas-
sified according to the NCI-Common Toxicity Criteria.
DTH scores after the first vaccine (baseline) and after the
other three vaccinations were compared between each
other by the Mann-Whitney test. For migration experi-
ments and comparison of mean fluorescence intensities
of DCs markers expression, statistical analysis was per-
formed by Student's t Test. P < 0.05 was considered signif-
icant.
Preparation of tumor apoptotic-necrotic cells
Apoptotic-necrotic (Apo-Nec) tumor cells were prepared
as a batch of four cell lines (MEL-XY1; MEL-XY2; MEL-XY3
and MEL-XX4) which have been previously described [21]
and were cultured from master cell banks after safety test-
ing for mycoplasma, viruses and bacteria. Cells were cul-
tured in melanoma medium (Dulbecco's Modified Eagle
Medium: nutrient Mixture F12 (1:1) (DMEM-F12) sup-
plemented with 2 mM glutamine, 20 nM sodium selenite,
100 μM ascorbic acid, 0.3 mg/ml galactose, 0.15 mg/ml
sodium pyruvate and 5 μg/ml insulin, 100 IU/ml penicil-
lin, 10 μg/ml streptomycin) plus 10% fetal bovine serum
(FBS) (Natocor, Córdoba, Argentina) in a Good Manufac-
turing Practice (GMP) core facility at the Centro de Inves-
tigaciones Oncológicas-FUCA. After gamma irradiation at
70 Gy (Siemens Lineal Accelerator), the cells were frozen
in freeze-medium (50% DMEM, 40% human albumin
and 10% DMSO) in liquid nitrogen until use. A soft agar
clonogenic assay performed in sextuplicate (104 seededJournal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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cells/well) was used to test that irradiated cells have lost
their proliferation ability compared to non-irradiated
control cells [29]. To prepare each vaccine, the cells were
thawed, washed and plated for 72 hs to complete the
apoptotic process (Apo-Nec cells). After that, the cells
were detached from the flasks, counted and resuspended
in AIM-V Medium (Therapeutic grade, GIBCO, Invitrogen
Corporation, Grand Island, N.Y).
DCs generation, characterization and vaccine preparation
DCs were generated at the Centro de Investigaciones
Oncológicas-FUCA according to GMP. PBMC were
obtained with a Continuous Flow Cell Separator (Fressen-
ius AS 104) using a modified protocol for granulocytes
isolation and a simple stage P1Y equipment. A peripheral
venous double punction without previous patient stimu-
lation was performed. Average values of initial hemo-
grams were: 6.8 × 103 per mm3 WBC (range 4.7–9.7 × 103/
mm3) and 29.5% lymphocytes (range 16.3–43%). An
average blood volume of 6 liters was processed (range 5–7
liters), with a mean product volume of 140.7 ml (range
99–250 ml). Mean PBMC yield was 7.5 × 109 cells (range
3.0–11.3 × 109). Whole procedure time was 90 min, and
no adverse events were observed. PBMC were purified by
Ficoll-Hypaque gradient centrifugation and frozen in
freeze-medium on day -30. To prepare each vaccine,
mononuclear cells were thawed one week before and
monocytes were allowed to adhere to plastic for 2 hs in
AIM-V Medium in 0.22 μm filter-capped culture flasks.
After removing the lymphocytes, immature DCs (iDCs)
were obtained by culturing for five days in AIM-V medium
in presence of 800 U/ml GM-CSF (rhGM-CSF; Molgra-
mostim, a generous gift from Dr. Esteban Corley, PC
Gene, Buenos Aires, Argentina) and 50 ng/ml IL-4 (rhIL-
4, Peprotech, Mexico). According to the vaccine dose, 5,
10, 15 or 20 × 106 DCs were cocultured with Apo-Nec cells
in a 3:1 as previously reported [21] in AIM-V medium for
48 hs at 37°C. On the vaccination day, cocultures were
centrifuged at 1200 rpm for 5 min, gently suspended in
300 μl and injected i.d. in an arm or thigh with intact
draining lymph nodes.
For each patient, quality controls (viability, cell count and
purity) were performed on all DCs preparations. Sterility
testing was performed on the starting leukapheresis prod-
uct, Apo-Nec cells and on the final coculture. DC prepara-
tions were characterized by flow cytometry (FACS) in a
FACScalibur (BD Biosciences, San José, CA, USA). The fol-
lowing mAbs were used: CD1a, CD11c, CD14, CD80,
CD83, CD86, HLA-DR, CD40, HLA ABC, CCR7 or the
corresponding isotype-matched controls, all from BD Bio-
sciences (San José, CA, USA).
DCs endocytosis was evaluated by incubating 106 cells
with 1 mg/ml FITC-dextran (FITC-Dx) (Sigma, St Louis,
CA) for 60 min at 37°C. Controls included tubes incu-
bated with FITC-Dx at 4°C to inhibit the endocytic proc-
ess and a basal uptake performed at 0 time point. After
washing with Phosphate Buffered Saline (PBS), FITC-Dx
uptake was quantified by FACS analysis (10,000 cells per
point). DCs migration was assessed in vitro before and
after co-culture with Apo-Nec cells, using a 48-wells chem-
otaxis chamber (AP 48 Neuroprobe Inc., Gaithersburg,
MD) as previously described [21]. iDCs cultured in the
presence of 2 μg/ml lipopolysaccharide (LPS) for 48 hs
were used as a maturation control for every DC experi-
ment.
Samples for immunological tests
To assess the humoral immune response, pre-vaccination
sera were obtained on day -7th and post-vaccination sera
on day 56th (fourteen days after the last vaccination),
aliquoted and stored at -80°C. PBMC were purified by
Ficoll-Hypaque gradient centrifugation from the leuka-
pheresis product (pre-vaccination PBMC) or from 40 ml
of heparinized blood obtained two weeks after the last
vaccination (post-vaccination PBMC) and frozen in
freeze-medium until testing. HLA typing for HLA-A*0201
was determined after incubation of patients' PBMC sam-
ples with mouse monoclonal anti-HLA-A2 FITC conju-
gated (BD-Pharmingen, San Jose, CA).
DTH reactions
On each vaccination day, DTH was performed in the fore-
arm with 2 × 106 Apo-Nec cells and the reaction was read
at 2, 24 and 48 hs. A DTH intensity value was established
as follows: 0: erythema < 0.5 cm diameter; 1: macular ery-
thema 0.5–1.0 cm; 2: macular erythema 1.0–2.0 cm; 3:
macular erythema > 2.0 cm or papular erythema<1.5
cm;4: papular erythema > 1.5 cm. The DTH score corre-
sponds to Σ all individual DTH intensities/4. DTH meas-
urements were not blinded.
Lymphocyte proliferation assay
In the case of patient #1 we could establish a melanoma
cell line from an axillary lymph node metastasis resected
before entry in this clinical study. Apo-Nec cells from
patient # 1's tumor cells (Apo-Nec#1) were obtained by
gamma irradiation as described above. Patient #1's DCs
cocultured with Apo-Nec # 1 cells (1.5 × 104 DCs + 5 × 103
Apo-Nec # 1) for 48 hs were plated in 96-well U-bottom
plates in triplicate and pre- and post-vaccination PBMC
from patient #1 (2 × 105) were thawed and added to DC/
Apo-Nec # 1. Controls were performed with PBMCs alone
or PBMCs plus Apo-Nec # 1 cells. As a positive control,
pre- and post-vaccination PBMC were treated with 5 μg/
ml phytohemagglutinin A (PHA, Gibco, Grand Island,
NY). After 96 hs of culture, cells were pulsed with [H]3
dThd (Amersham, 1 μCi/well) during the last 16 hs. The
cells were lysed with a Cell Harvester (Nunc, Rochester,Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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NY) and radioactivity was measured in a Liquid Scintilla-
tion Counter. The experiments were performed in tripli-
cate and the mean ± SD is shown.
Immunomonitoring
Staining with HLA/peptide tetramers
Phycoerythrin or allophycocyanin-conjugated HLA-
A*0201 tetramers (AAGIGILTV or KTWGQYWQV, respec-
tively) were kindly supplied by the NIH Tetramer Core
Facility (Emory University, Atlanta GA) and used to iden-
tify specific clones for Melan A/MART-1 or gp100 respec-
tively. Pre- and post-vaccination PBMC samples from
HLA-A*0201 patients were thawed and incubated for 2 hs
at 37°C in AIM-V medium, stained with tetramers at 37°C
for 15 min and immediately chilled on ice. Samples were
then incubated with anti-CD8 FITC (BD Biosciences, San
Jose CA) at 4°C for additional 40 min, washed with PBS
and analyzed by FACS. As positive controls we used Melan
A/MART-1 (M27) or gp100 (G154) specific HLA A*0201
restricted CTL clones [30] expanded in RPMI medium in
14-day cycles in the presence of 30 ng/ml anti-CD3 anti-
body (OKT-3, BD Biosciences) and serial 300 UI/ml IL-2
(Chiron BV) every 3 days plus 10% heat-inactivated AB
human serum and antibiotics. Negative controls were per-
formed with PBMC samples from healthy HLA-A*0201
donors.
ELISpot assay for IFN-γ release from single Ag-specific T cells
In HLA-A*0201 patients, stimulator DCs were prepared
from CD14+  cells purified from PBMC using CD14
MicroBeads and autoMACS separator (Miltenyi Biotec,
Paris, France), cultured for 5 days in synthetic medium
SYN-H (AbCys, Paris, France) containing 100 ng/ml
rhGM-CSF and 20 ng/ml IL-4, and maturated with 10 μg/
ml LPS for 2 additional days. Mature DCs were pulsed for
1 h at 37°C with 10 μg/ml peptide diluted in SYN-H
medium, washed and used as stimulators for CD8+ T
cells. We used gp100 (KTWGQYWQV), MelanA/MART-1
(AAGIGILTV) and Flu58–66 (GILGFVFTL) (influenza virus)
HLA A*0201 restricted peptides. Nitrocellulose plates
(96-wells; MAIPS 450; Millipore, Bedford, MA) were
coated overnight at 4°C with 10 μg/ml anti-human IFN-γ
mAb (Mabtech, Nacka, Sweden) in 50 mM carbonate-
bicarbonate buffer pH 9.6, washed and blocked with
IMDM (Iscove Modified Dulbecco's Medium, Gibco-Inv-
itrogen, Cergy Pontoise, France)/10% human AB serum
(Biowest, Nuaille, France) for 1 h at 37°C. PBMC were
stained with anti-CD8 PC5 (Beckman Coulter) and
counted by FACS analysis. Effector cells (E) (105 CD8+ T
cells/well) were seeded in 100 μL medium and stimulator
cells (S) added to reach an E/S ratio of 10: 1 in a total of
200  μL/well. After 24 hs incubation, the supernatants
were separated and wells were washed 5 times with 0.1%
Tween-20 in PBS. Plates were incubated 2 hs at room tem-
perature (RT) with 1 μg/ml biotinylated mouse anti-
human IFN-γ mAb (Mabtech) in PBS/HSA (human serum
albumin) (0.4 g/L). After extensive washing with 0.1%
Tween-20 in PBS, 1: 1000 streptavidin-alkaline phos-
phatase (Mabtech) in PBS/HSA was added and incubated
for 1 h at RT. The plates were then washed and incubated
with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue
tetrazolium substrate for 30 min at RT (Mabtech). Color
developing was stopped by washing under running tap
water. After drying, IFN-γ secreting T cells were counted
using an automated image analysis system ELISpot reader
(AID, Strassberg, Germany). Positive controls were done
with DCs pulsed with Flu58–66 peptide. Negative controls
were either non-pulsed DCs or DCs pulsed with
CMV495–503 (NLVPMVATV) peptide. Each experiment was
performed in triplicate.
Determination of humoral responses
Indirect Immunofluorescence
The presence of anti-melanoma antibodies was investi-
gated by incubation of live melanoma cell lines that com-
prise Apo-Nec vaccine (mixed in equal proportions) with
pre- and post- vaccination sera for 1 h and detected as pre-
viously described [31].
Western Blots
Protein extracts were prepared from the four cell lines that
comprise Apo-Nec vaccine by lysis with 1% NP40, homo-
geneized with a Polytron (Brinkmann Instruments, USA)
and centrifuged for 40 min at 10.000 ×g. The protein con-
centration was measured according to Lowry [32]. Protein
extracts were prepared equally from the human breast
cancer cell line IIB-BR-G [33] and used to assess specificity
in the Western Blots. Western blots were performed as
described [31] using pre- and post-vaccination sera as pri-
mary antibodies.
IL-10 promotor polymorphism analysis
DNA was extracted from heparinized blood samples,
using CTAB extraction protocol [34]. PCR for genotyping
IL-10 -1082 was performed using primers and amplifica-
tion conditions described by Marka et al [35]. The reverse
primer contained an additional Mnl I restriction site
within the primer recognition sequence. After amplifica-
tion, PCR products were purified from an agarose gel with
a home-made glass fiber column. RFLP was performed by
overnight digestion with Mnl I restriction endonuclease
(New England Biolabs, Beverly, USA). The products were
analyzed after electrophoresis on 3% agarose gel and
ethidium bromide staining (Gibco, BRL). Three different
genotypes have been associated to different in vitro IL-10
production: GG (high production), AG (moderate pro-
duction) and AA (low production). Results of the RFLP
were interpreted as follows: 94, 65 and 39 bp bands cor-
respond to GG genotype; 133, 94, 65 and 39 bp bandsJournal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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correspond to AG genotype and 133 and 65 bp bands cor-
respond to AA genotype.
IL-10 measured by ELISA
IL-10 concentrations were determined in the sera of vacci-
nated patients before (pre-vaccination serum) and three
weeks after the fourth vaccination (post-vaccination
serum). Sera were frozen at -80°C until tested by ELISA in
triplicate (OptEIA IL-10, BD Biosciences, San Diego, CA).
To measure in vitro IL-10 production by patient's PBMC in
response to LPS or PHA stimulation, 1 × 106 cells were
thawed, plated in 2 ml AIMV medium in 35 mm petri
dishes for 24 hs, and were either untreated or treated with
10 μg/ml LPS or 20 μg/ml PHA for another 24 hs [36].
Culture supernatants were collected, centrifuged at 2000
rpm and tested by ELISA as indicated above. A calibration
curve was performed for each experiment and the sample
concentration was calculated by log-log regression analy-
sis using Cembal 2.2 software.
Results
Patients
This Phase I Study was performed between October 2004
and September 2005, on sixteen melanoma patients from
the Instituto Alexander Fleming. Their characteristics are
listed in Table 1. The mean age was 42 years (range 17–60
years-old). There were five females and eleven males. One
patient had AJCC stage IIC melanoma, eight had stage III
melanoma and seven had stage IV melanoma (five M1b
and two M1c). Seven of eight Stage III patients received
IFN-α treatment before entering this study: two com-
pleted their treatment; four interrupted it due to progres-
sive disease, and one due to hepatic toxicity. Cohorts of
four patients were vaccinated with 5, 10, 15 or 20 × 106
DCs cocultured with Apo-Nec cells (DC/Apo-Nec vac-
cine). Every patient received one dose of DC/Apo-Nec
(0.3 ml) without adjuvant every two weeks. Patient #7
was withdrawn from the protocol after the second vacci-
nation due to rapidly progressing disease after a sport
trauma in his right thigh and uncontrolled infection; this
patient was not replaced.
Characteristics of DC/Apo-Nec vaccine obtained for 
melanoma patients
For each vaccination, DCs were generated from a frozen
aliquot of PBMC after culture of adherent monocytes in
serum-free medium in the presence of rhGM-CSF and
rhIL-4. At day 5, immature DCs (iDCs), were obtained
which were CD14- /CD11c+ (95.1 ± 3.6%) and CD1a+ (70
± 9%, data not shown). Approximately 3 × 106 DCs were
obtained from 1 × 108  PBMC plated in serum-free
medium. At day 5, iDCs were co-cultured with Apo-Nec
cells, incubated for 48 hs, resuspended as described under
Methods and injected into patients. In Figure 1 we sum-
marize the characteristics of iDCs and DC/Apo-Nec vac-
cine obtained for the melanoma patients participating in
the study. We found that patient's iDCs were able to
phagocytose Apo-Nec cells (42.3 ± 13.7%, PKH 26/
PKH67 double labeled population, n = 15), and in Figure
1A patient # 1 DCs phagocytosis of Apo-Nec cells is
shown as an example. The ability of Apo-Nec cells to
influence the maturation process of monocyte-derived
DCs was examined by means of FACS measurement of
specific DC markers. Phagocytosis of Apo-Nec cells
yielded a mature-DC phenotype (Figure 1B) as compared
Table 1: Characteristics of the patients participating in the Clinical Study
Pt # Sex Age Stage Mts Site MN Cells obtained 
(×109cells)
Dose of DC/Apo-Nec 
(×106cells)
No. Vacc Clin. Evolution 
(12/1/07)
IL-10 Promoter 
Genotype
1 F 42 III LN 3.5 5 4 P (10 m) AA
2 F 57 III ND 3.6 5 4 NED (62 m+) AG
3 M 32 III ND 3.3 5 4 NED (43 m+) AA
4 F 17 III ND 4.4 5 4 NED (53 m+) AG
5 M5 6 I V L , S C 5 1 0 4 P  ( 4  m ) A A
6 M 60 III ND 1.5 3 4 NED (45 m+) AA
7 M2 7 I V S C 4 . 2 1 0 2 W P  ( 1  m ) A A
8 M2 6 I V N D 3 . 6 1 0 4 P  ( 7  m ) A A
9 F 42 III ND 7.5 15 4 NED (79m+) AG
10 M3 4 I V L N 6 . 2 1 5 4 P  ( 1 1  m ) A G
11 M4 4 I V L 4 . 7 1 5 4 P  ( 4  m ) A G
12 M 56 III ND 8 15 4 NED (33m+) AG
13 M 47 IIC ND 9.3 20 4 NED (34 m+) AA
14 M 30 III ND 7.5 20 4 NED (47 m+) GG
15 M5 2 I V L N 6 2 0 4 P  ( 1 0  m ) A A
16 F5 7 I V S C 8 . 2 2 0 4 P ( 6  m ) A A
ND: non-detectable disease after surgery; SC: subcutaneous; L: Lung; LN: Lymph node; NED: non-evident disease; P: progression; D: deceased. WP: 
withdrawn from protocol. m: months of follow-up from last surgery.Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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to a LPS-incubated control. DCs maturation was evi-
denced by increased expression of CD83, CD80, CD86,
HLA class I and II and CD40. Also, after phagocytosis, a
75.2% ± 16 reduction in FITC-Dx endocytosis was
observed compared to iDCs (Figure 1C).
Chemokine (C-C motif) receptor 7 (CCR7) was clearly
upregulated upon Apo-Nec phagocytosis in DCs from all
patients (Figure 1B) and this correlated with DCs migra-
tion towards MIP-3 beta in vitro. As an example, we show
in Figure 1D patient # 9 DCs migration towards MIP-1α
and MIP-3β. Immature DCs (9.6% CCR7+, MFI 23.3)
migrated to MIP-1 α but failed to respond to MIP-3β;
instead DC/Apo-Nec cells (81.8% CCR7+, MFI: 41.2)
clearly increased their migration to MIP-3-β but mini-
mally responded to MIP-1α.
Toxicity to DC/Apo-Nec Vaccine
Except for patient # 6, in whom the yield of PBMC was
low, and therefore the expected dose of 10 × 106 DC/Apo-
Nec could not be attained (he only received 3 × 106 DC/
Apo-Nec per vaccine), all other patients received the
expected dose of DC/Apo-Nec. DC/Apo-Nec vaccine was
well tolerated and only mild toxicity, always Grade 1, was
found. Weak local reactions at the vaccination and DTH
sites, consisting in erythema and papulae, were observed.
No clinical manifestations of autoimmune disease devel-
oped in any patient (Table 2).
Characteristics of DC/Apo-Nec vaccine Figure 1
Characteristics of DC/Apo-Nec vaccine. A-DCs phagocytosis. Patient #1 results are shown. Apo-Nec cells (green 
labeled) phagocytosis by DCs (red-labeled, left panel) was evaluated as described under Methods. DCs and Apo-Nec cells were 
co-cultured for 48 hs at 37°C (middle panel) or at 4°C to inhibit phagocytosis (right panel). Total DCs (red labeled population) 
was gated and the percentage of double positive cells (DC/Apo-Nec) was calculated. B-DC Maturation. Markers expression 
of iDCs, DC/Apo Nec cells and DCs + LPS from all vaccinated patients (n = 15) was evaluated by FACS using monoclonal anti-
bodies as described under methods. Results are mean ± SD percentage of positive cells, MFI: mean fluorescence intensities. C- 
DC endocytosis. FITC-Dx uptake of iDCs DC/Apo-Nec cells and DC + LPS of all vaccinated patients (n = 15). Results are 
indicated as mean ± SD percentage of FITC-Dx positive cells after 90 min incubation and washing. *: diferences with iDCs were 
statistically significant (Student's t test). D-DC migration. In vitro migration towards MIP-1α and MIP-3β was measured as 
described under methods. iDCs, DC/Apo-Nec and DCs + LPS from patient # 9 are shown (mean ± SD, assayed in triplicate).Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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Clinical evolution in vaccinated patients
As of December 2007, with a mean follow-up of 49.5
months post-surgery (33–79 months), the stage IIC
patient is NED; 7/8 (87.5%) stage III patients are NED
and 7/7 stage IV patients experienced disease progression.
No regressions of metastatic lesions were observed in this
study.
Immune responses
DTH
DTH reactions to Apo-Nec cells were measured at each
vaccination. The intensity of the reaction and the DTH
score were determined as described under Methods. Only
few patients (6/15) had a weak pre-vaccination DTH reac-
tion against Apo-Nec cells. DTH test revealed vaccination
– induced Apo-Nec cells specific reactivity in all patients,
since DTH score was significantly higher after the second
DC/Apo-Nec vaccine compared to the basal reaction
observed after the first-vaccination (Mann Whitney test P
= 0.0039, n = 15) (data not shown). Although without
reaching statistical significance, DTH scores were higher in
NED patients than in those who experienced disease pro-
gression. The increase in DC/Apo-Nec number per vacci-
nation did not increase the DTH score significantly (not
shown).
Patient #1 had a DTH response to her autologous Apo-
Nec cells after vaccination, demonstrating that vaccina-
tion with allogeneic DC/Apo-Nec cells induced immunity
against her own melanoma Ags (not shown).
Humoral response
No humoral responses were detected against the live
melanoma cells that comprise the vaccine, either before or
after vaccination, as determined by FACS analysis. We also
investigated the presence of anti- Apo-Nec cells antibodies
in pre- and post- vaccination sera by Western blot. In four
patients (#3, #4, # and #16) we observed only a faint pro-
tein band (>200 kDa) in post-vaccination sera which was
not present in breast cancer cells extract used as unspecific
control (not shown).
Lymphocyte proliferation in response to autologous tumor 
cells (patient # 1)
In the case of patient #1, an autologous melanoma cell
line was established, allowing us to analyze if lym-
phocytes were primed by DC/Apo-Nec vaccination (allo-
geneic cells) and recognized autologous Ags. We
measured pre- and post-vaccination PBMC proliferation
after a five-day coculture of mononuclear cells with Apo-
Nec#1 cells (irradiated patient #1's tumor cells) or DC/
Apo-Nec as described under Methods. As we had previ-
ously demonstrated, Apo-Nec cells alone were not able to
stimulate PBMC by their own, probably due to the loss of
HLA-class I molecules at the cell surface during the apop-
totic process [21] (Figure 2). Instead, post-vaccination
PBMC proliferated approximately 10-fold more than pre-
vaccination lymphocytes in response to DC/Apo-Nec#1
cells, demonstrating that after vaccination with DC/Apo-
Nec, lymphocyte clones recognizing Ags shared by the
Apo-Nec mixture and the patient's tumor cells had
expanded.
Tetramer analysis and IFN-γ- ELISpot for gp100 and Melan 
A/MART-1
7/15 patients enrolled in this Phase I Clinical Trial had the
HLA-A*0201 class I haplotype, and thus HLA-restricted
tumor-specific responses could be studied in their PBMC
samples. We analyzed anti-gp100 and Melan A/MART-1
specific CD8+T cell responses induced by DC/Apo-Nec
vaccine, by: i) specific HLA/peptide tetramer binding and
ii) IFN-γ ELISPot, directly from peripheral blood samples.
i) For five patients enough PBMC were obtained before
and 14 days after the fourth vaccination to analyze the
presence of gp100 and Melan A/MART-1 specific CD8+T
Table 2: Toxicities associated with DC/Apo-Nec vaccination (*)
Symptoms DC/Apo-Nec 5 × 106 DC/Apo-Nec 10 × 106 DC/Apo-Nec 15 × 106 DC/Apo-Nec 20 × 106
Fatigue 1/4 1/3 0/4 0/4
Headache 1/4 0/3 0/4 0/4
Chills 1/4 0/3 0/4 0/4
Abdominal cramps 0/4 0/3 0/4 1/4
Local reaction 4/4 3/3 4/4 4/4
Astenia 0/4 1/3 0/4 0/4
Nausea 0/4 0/3 0/4 1/4
Abdominal pain 0/4 0/3 0/4 1/4
Vomiting 0/4 0/3 0/4 1/4
Anorexia 0/4 1/3 0/4 0/4
Diarrea 0/4 0/3 0/4 1/4
Myalgia 1/4 0/3 1/4 0/4
(*) Toxicity was Grade 1 in all cases.Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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cells by tetramer staining. We observed an irregular trend.
In some patients, i.e. patients #2 and #6, tetramer positive
cells increased several fold to over 1% for both Ags tested
after DC/Apo-Nec vaccination. Patient #8 had a high fre-
quency of anti-Melan A/MART-1 reactive CD8+T cells
before treatment that did not change after vaccination
(pre: 0.98%; post: 0.93%); instead, gp100-specific T cells
decreased after vaccination (pre: 0.93%; post: 0.25%).
Patient #16 had a high number of pre-vaccination CD8+
gp100- and Melan A/MART-1-specific lymphocytes (1.9
and 1.7%, respectively) which decreased 50% after vacci-
nation (1 and 1.1%, respectively). No staining was
observed in an HLA-matched healthy donor under the
same conditions (not shown).
ii) As IFN-γ plays a crucial role in the induction of tumor-
protecting T cell immunity, it is important to measure the
frequency of Ag-specific individual IFN-γ secreting CD8+
T cells in treated patients. Total pre-and post-vaccination
PBMC were tested for release of IFN-γ in ELISpot after 24
hs incubation with autologous DCs pulsed with gp100 or
Melan A/MART-1 peptides and, as a control, influenza
(flu58–66) peptides. This assay was evaluated in 5/7 HLA-
A*0201 patients as shown in Figure 3. We observed that
in two patients (#5 and #16) DC/Apo-Nec vaccination
induced an increase of anti- gp100 and MelanA/MART-1
IFN-γ secreting CD8+T cells. For gp100, frequencies of 70
× 10-5 and 35 × 10-5 CD8+ T cells secreting IFN-γ were
induced, while pre-vaccination values were negligible. For
patient #2 the situation was peculiar since this patient had
a high frequency of IFN-γ secreting CD8+ clones specific
for gp100 and Melan A/MART-1 even before vaccination,
and this high frequency did not change (gp100) or
slightly decreased (Melan A/MART-1) after vaccination.
Patients #15 and # 8 had intermediate or negligible num-
bers of spots at baseline (pre-vaccination) and after vacci-
nation. Positive controls performed with Flu58–66 peptide
detected 15–20 spots in each sample (not shown).
IL-10 promoter polymorphism
Polymorphism in the IL-10 promoter has been associated
with differential in vitro secretion of IL-10, and various
authors have reported that these polymorphisms may
influence the outcome of melanoma patients [37,38,22].
Genotyping for -1082 (G/A) includes three categories: GG
is associated with high in vitro tumor IL-10 production,
whereas AG and AA, are associated with intermediate and
low production, respectively [22]. As the AA genotype has
been shown to be associated with decreased survival in
patients with advanced disease [37] we analyzed the -
1082 genotype in all patients. In order to choose a com-
mon starting point of observation, the influence of IL-10
polymorphism on the interval that elapses between sur-
gery due to lymph node involvement (stage III) and pro-
gression to distant metastases (stage IV) was studied.
Therefore, patient # 13 was not included in this analysis,
Detection of antigen-specific IFN-γ secreting CD8+T cells by  ELISpot analysis Figure 3
Detection of antigen-specific IFN-γ secreting CD8+T 
cells by ELISpot analysis. ELISpot assay was performed as 
described under Methods. Number of individual gp100 and 
Melan A/MART-1 specific spots/105 CD8+T cells from pre 
and post DC/Apo-Nec vaccination samples are shown for 5/
7 HLA-A*0201 patients. Data represents mean values of trip-
licates. Background numbers of spots were set with non – 
pulsed DCs and subtracted from the number of spots.
Patient#1's lymphocytes in vitro proliferation in response to  autologous tumor Ags presented by DCs Figure 2
Patient#1's lymphocytes in vitro proliferation in 
response to autologous tumor Ags presented by 
DCs. Pre and post vaccination Patient#1 PBMC were incu-
bated either alone, with Apo-Nec#1 cells prepared from 
patient#1 tumor cells or with DC/Apo-Nec#1 cells; (H3) 
dThd incorporation was measured as described under Meth-
ods. Results represent mean ± SD cpm (counts per minute) 
of triplicates. Positive controls incubated with PHA incorpo-
rated more than 7 × 104 cpm (not shown).Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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since he was at clinical stage IIC. Although numbers are
small and should be cautiously interpreted, as observed in
Figure 4A patients with AA genotype were associated with
more rapid disease progression after lymph node surgery
than patients with AG/GG genotypes (P = 0.04, curves
compared by Chi Square test). To correlate genotype with
the actual IL-10 production by stimulated PBMC, in vitro
IL-10 secretion by pre-vaccination PBMC from all patients
was investigated after LPS or PHA stimulation. As
observed in Figure 4B, PBMC from AA patients secreted
less IL-10 in response to both stimuli than those from AG/
GG patients; although the differences were not statistically
significant (Mann Whitney Test), the trend was clear.
Control PBMC (not stimulated) secreted less than 7 pg IL
10/106 /ml (detection level in ELISA).
Discussion
In the present Phase I study performed on sixteen
melanoma patients stages IIC, III and IV, we have assayed
a therapeutic DC-based vaccine (DC/Apo-Nec) in which
autologous iDCs were loaded with a mixture of apoptotic/
necrotic allogeneic melanoma cell lines. Accordingly to
our preclinical results obtained with DCs from healthy
donors [21], we report here that phagocytosis of Apo-Nec
cells induced DCs maturation, a requirement reported as
essential to trigger an effective immune response [39,40].
These findings contrast with those of Neves et al [41] who
reported hat monocyte-derived DCs from cancer patients
mature less efficiently than those from healthy volunteers.
We have also previously demonstrated that this strategy
allows Ag processing and cross-presentation for CTL prim-
ing [21], and therefore permits the "natural" processing
and epitope selection of known as well as yet unknown
Ags, allowing presentation of a great peptide diversity on
various HLA-haplotypes. DC/Apo-Nec vaccine was well
tolerated and safe, since only mild toxicity was found, and
induced cellular responses, since DTH reactions to the
Apo-Nec cells increased in all patients. DTH reactions
have been used as an indicative of in vivo induction of
immunological memory, and some authors have reported
a positive correlation between DTH and patients outcome
[42,43].
DTH was not exclusively triggered by the allogeneic vac-
cine, since at least in patient #1 we observed, after vacci-
nation, a positive DTH to the patient's own irradiated
tumor cells, demonstrating that DTH also took place
when autologous Ags were used. For this patient we also
found specific in vitro PBMC proliferation to DC/Apo-
Nec#1 cells after vaccination. We have also demonstrated
by ELISpot analysis that vaccination with DC/Apo-Nec
elicited high numbers of anti-MelanA/MART1 and anti-
gp100 specific CD8+T lymphocytes in 2/5 analyzed HLA-
A*0201 patients; 2/5 patients had invariant high or inter-
mediate levels of specific CD8+T lymphocytes, and 1/5
patient did not develop any specific T cell response. We
have also used the tetramer binding analysis to quantify
CD8+T cells recognizing the same two Ags. The results
observed with this methodology were irregular, with
some patients increasing their tetramer-positive PBMC to
over 1% for one Ag while decreasing for the other. It
should be taken into consideration that the number of cir-
culating PBMC specific for a given Ag reflects a balance
between production and migration to peripheral tissues,
perhaps where tumor may be present [44]. Several obser-
vations suggest that MelanA/MART-1-specific CD8+ T
cells can mediate tumor regression. This conclusion is
based on the cytolytic activity of MelanA/MART-1-
tetramer+ lymphocytes in culture [45], on the poor prog-
nosis for patients with MelanA/MART-1-negative primary
melanoma [46] as well as on results of adoptive immuno-
therapy with autologous MelanA/MART-1-specific CTL
clones [47]. Most antitumor vaccination attempts failed to
elicit significant specific T cells numbers, which remained
either undetectable [48] or in low frequencies in ex vivo
Influence of Interleukin-10 -1082 promoter genotype in dis- ease progression Figure 4
Influence of Interleukin-10 -1082 promoter genotype 
in disease progression. A- Disease progression was calcu-
lated in months from the last surgery, reported as of Decem-
ber 2007. Differences between curves were significant (P = 
0.04, Chi Square test). B- In vitro IL-10 secretion by patients' 
PBMC in response to LPS or PHA. Control PBMC (not stim-
ulated) did not secrete IL-10. Culture supernatants were 
tested in triplicate by ELISA as described under methods. 
Lines represent median value in each case. Mann Whitney's 
test showed that differences between AA and AG/GG geno-
types were not statistically significant. AA (PHA) vs AG/GG 
(PHA) P value: 0.6; AA (LPS) vs AG/GG (LPS) P value: 0.25.Journal of Translational Medicine 2008, 6:6 http://www.translational-medicine.com/content/6/1/6
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assays [49]. Besides, T cells need to be in the correct state
of activation to perform their functions and mediate effec-
tive immune protection against cancer [50]. It is remarka-
ble that, for all analyzed patients, the numbers of CTLp
(quantified by ELISpot) were strikingly lower than the
number of tetramer-positive CD8+T lymphocytes (data
not shown), thus suggesting that despite Ag recognition,
their functional properties were impaired. The possibility
that not all tetramer-positive cells may be functional has
also been demonstrated in EBV, HIV-1 and tumor-associ-
ated antigen-specific CD8+T cells [51-53]. Besides, even
the induction of high numbers of circulating Ag-specific
CD8+T lymphocytes may not be related to clinical benefit
since, as recently reported [54], profound differences can
be found between tumor-specific CD8+ T cells in circula-
tion and those isolated and/or studied in the tumor
microenvironment, where the presence of high levels of
FoxP3+ regulatory T cells could influence their functional
status. These evidences, among others [55], suggest that a
strong phenomenon of immune tolerance takes place
within the tumor including the presence of regulatory T
cells, thus hampering effective T cell functionality. This
effect is probably more important as the tumor mass
increases, and less so when tumor cells are fewer in
number, as in the adjuvant setting.
Recent reports tried to elucidate if certain polymorphisms
that result in functional changes in cytokine genes could
influence susceptibility, disease progression or survival in
cancer patients. In melanoma, the AA genotype has been
associated to a poorer prognosis, supporting the recent
findings that IL-10 has an anti-tumor effect possibly via
inhibition of angiogenesis [27,28]. The presence of the AA
genotype (lower IL-10 production) has also been associ-
ated to the development of prostate cancer and renal cell
carcinoma [56,57] but not conclusively to melanoma sus-
ceptibility [24,58]. Also, a recent report [22] has suggested
that polymorphisms associated with low expression of
anti-inflammatory IL-10 and TGF-β1 and immunomodu-
latory TNF-α, IFN-γ and IL-6 could be involved in the
mechanisms of cancer progression and escape from
immune surveillance. A dual role for IL-10 in the tumor
microenvironment has been hypothesized: IL-10 is
secreted constitutively by some tumors where it would
have two major roles (1) to increase NK cell tumor killing,
release of Ags and possibly APC uptake of damaged tumor
cells and (2) to inhibit APC maturation with consequent
maintenance of the ability to uptake Ags, remaining in situ
rather than migrating to regional lymph nodes. Thus, IL-
10 would maintain a chronic inflammatory state within
the tumor microenvironment and it would also inhibit
recruitment and activation of adaptative immune system
[26].
We analyzed if the IL-10 -1082 promoter polymorphism
in our group of patients could be related to the rate of dis-
ease progression from stage III to stage IV. Although the
number of patients was small, we found a significant cor-
relation between AA genotype and rate of disease progres-
sion. The genotype and phenotype were correlated, since
after measuring in vitro IL-10 secretion of patients' PBMC
treated with LPS or PHA. AA patients showed a trend to
lower IL-10 production than AG/GG patients, although
the difference was not statistically significant probably
due to the small number of patients analyzed. Thus, our
results suggest that AA patients (low IL-10 in vitro produc-
tion) had a worse outcome than the intermediate/high IL-
10 producing patients. In this study, the number of
patients was too small to analyze the correlation between
IL-10 genotype and response to vaccine, since 5/7 (71%)
stage IV patients had the most unfavorable genotype (AA)
versus 3/8 (37%) for stage III patients.
Although we did not observe clinical responses in meta-
static melanoma patients, 87.5% of the stage III patients
are disease-free with a mean follow up of 49.5 months
after surgery. Thus, we believe that this vaccination
approach could benefit patients in the adjuvant setting
since the limited number of activated Ag-specific CD8+
lymphocytes would be only able to eliminate micrometa-
static lesions, thus protecting patients from tumor relapse.
Conclusion
Our results demonstrate that the use of ex vivo generated
DCs loaded with a mixture of allogeneic melanoma cell
lines is safe and it elicits immune response against tumor
Ags, shown by: i) an increased DTH; ii) an increase of anti-
Melan A/MART-1 and anti-gp100 lymphocytes; iii) activa-
tion of lymphocytes directed to as yet unspecified Ags. An
association of IL-10-1082 AA promoter polymorphism
with worst prognosis in melanoma is suggested and
should be further investigated. Larger numbers of patients
should be treated with DC/Apo-Nec vaccine to evaluate its
clinical efficacy in a Phase II clinical trial.
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